$PTN News

Last published 1mo ago

1mo agoPTNFourth Quarter Fiscal Year 2026 Financial Teleconference and Webcast - PALATIN TECHNOLOGIES INCEarnings Call TranscriptsWelcome to Palatin's 4th Quarter and Fiscal Year-End 2026 Operating Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If
1mo agoPTNPalatin Reports Fiscal Year 2026 Financial Results and Provides Business UpdatePR NewswirePalatin Technologies, Inc. (Nasdaq: PTN), a biopharmaceutical company developing medicines that target the melanocortin receptor ("MCR") system,...
5mo agoPTNPalatin to Begin Trading on Nasdaq Stock ExchangePR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting ...
6mo agoPTNPalatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business UpdatePR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing medicines that target the melanocortin receptor (MCR) system, ...
8mo agoPTNPalatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate UpdatePR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
12mo agoPTNFirst Quarter Fiscal Year 2026 Financial Teleconference and Webcast - PALATIN TECHNOLOGIES INCEarnings Call TranscriptsGreetings. Welcome to Palatine's first quarter fiscal year 2026 Operating Results Conference Call. At this time, all participants are on the listen-only mode. A question-and-answer session will follow the formal presenta
12mo agoPTNPalatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate UpdatePR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
12mo agoPTNPalatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment OptionPR NewswirePalatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based...
1y agoPTNPalatin Expects $11.5 Million Financing to Cure NYSE American Delisting NoticePR NewswirePalatin Technologies, Inc. (the "Company" or "Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based...
1y agoPTNPalatin Technologies Announces Pricing of up to $23 Million Public OfferingPR NewswirePalatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based...
1y agoPTNPalatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma TherapyPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company advancing innovative treatments targeting the melanocortin receptor...
1y agoPTNPalatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye DiseasePR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
1y agoPTNPalatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and TirzepatidePR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
1y agoPTNPalatin Appeals NYSE American Notice of DelistingPR NewswirePalatin Technologies, Inc. (the "Company") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules...
1y agoPTNPalatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to AppealPR NewswirePalatin Technologies, Inc. (the "Company") (NYSE American:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules...
1y agoPTNPalatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring MeetingPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
1y agoPTNPalatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity StudyPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
1y agoPTNPalatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177PR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
1y agoPTNPalatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor DeficiencyPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
1y agoPTNPalatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business UpdatePR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
1y agoPTNPalatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025PR NewswirePalatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025,...
1y agoPTNPalatin Announces $4.7 Million Registered Direct Offering and Concurrent Private PlacementPR NewswirePalatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based...
1y agoPTNPalatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP TirzepatidePR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
1y agoPTNPalatin Provides Update on Anticipated 2025 Corporate MilestonesPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
1y agoPTNPalatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic NephropathyPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
1y agoPTNPalatin Announces Exercise of Warrants for Approximately $3.4 Million Gross ProceedsPR NewswirePalatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based...
1y agoPTNPalatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative ColitisPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
1y agoPTNPalatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call TranscriptEarnings Call Transcripts
1y agoPTNPalatin Reports First Quarter Fiscal Year 2025 Operating/Financial ResultsPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
2y agoPTNPalatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024PR NewswirePalatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2025 operating results on Thursday, November 14, 2024,...
2y agoPTNPalatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024PR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
2y agoPTNPalatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of ObesityPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
2y agoPTNInflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics SymposiumPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
2y agoPTNPalatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics SymposiumPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
2y agoPTNPalatin Receives Notice of Non-Compliance from NYSE AmericanPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
2y agoPTNPalatin Technologies, Inc. (PTN) Q4 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoPTNPalatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated MilestonesPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
2y agoPTNPalatin to Report Fourth Quarter and Fiscal Year End 2024 ResultsPR NewswirePalatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2024 operating results on Tuesday, October 1,...
2y agoPTNPalatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated MilestonesPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
2y agoPTNFDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)PR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
2y agoPTNFirst Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of ObesityPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
2y agoPTNPalatin Announces Exercise of Warrants for Approximately $6.1 Million Gross ProceedsPR NewswirePalatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based...
2y agoPTNPalatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)PR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
2y agoPTNPalatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of ObesityPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
2y agoPTNPalatin Technologies, Inc. (PTN) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoPTNPalatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdatePR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
2y agoPTNPalatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024PR NewswirePalatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2024 operating results on Wednesday, May 15, 2024, before ...
2y agoPTNPalatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of ObesityPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
2y agoPTNPalatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024PR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
2y agoPTNPalatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024PR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...